Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-01

Study Completion Date

2020-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate specialized proresolving mediators (SPM) concentrations for the first time in subjects infected with Pneumocystis jirovecii. SPM will be measured in blood and urine in patients with favourable or unfavourable outcome of Pneumocystis pneumonia and in patients colonized by Pneumocystis jirovecii. The hypothesis is that low levels of SPM in the blood could be predictive of a negative outcome of pneumocystosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

NCT05458752

Pneumocystis Jirovecii Infection

COMPLETED

Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii

NCT06431958

Pneumocystis Pneumonia

ACTIVE_NOT_RECRUITING

Specific Genotypes/Phenotypes of Pneumocystis Jirovecii in Solid Organ Transplant Recipients: Potential Involvement of Mycophenolic Acid

NCT05452148

Transplantation Pulmonary Diseases

COMPLETED

Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

NCT03978559

Pneumocystis Pneumonia

UNKNOWN PHASE4

Corticosteroids for PJP in Non-HIV Immunocompromised Adults

NCT07152613

Pneumocystis Jiroveci Pneumonia

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pneumocystis pneumonia is a severe fungal disease threatening immunosuppressed subjects such as patients suffering from AIDS, oncohematological diseases or solid organ transplanted patients. The disease is characterized by an important inflammation in the infected lungs which is mainly responsible for lungs lesions. Despite an adequate treatment introduction, mortality is still around 20% which can not be explained by a treatment resistance. Specialized proresolving mediators (SPM), including lipoxins, maresins, protectins and resolvins, are newly described molecules implicated in the active process of inflammation resolution. The investigators hypothesis in this study is that high levels of SPM could be predictive of a good resolution of the harmful inflammation, thus a good evolution of the disease, in adequate pneumocystosis therapy conditions. On the contrary, low levels of SPM could be predictive of an unfavourable outcome despite a treatment targeting Pneumocystis jirovecii

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia, Pneumocystis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pneumocystosis with favourable evolution

patients with a favourable pneumocystosis outcome

Group Type OTHER

Blood sampling

Intervention Type OTHER

6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

urine sampling

Intervention Type OTHER

2 urine sample (1 at J0 and 1 at J7)

pneumocystosis with unfavourable outcome

patients with unfavourable pneumocystosis outcome

Group Type OTHER

Blood sampling

Intervention Type OTHER

6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

urine sampling

Intervention Type OTHER

2 urine sample (1 at J0 and 1 at J7)

Pneumocystis colonization

subject colonized by Pneumocystis jirovecii

Group Type OTHER

Blood sampling

Intervention Type OTHER

6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

urine sampling

Intervention Type OTHER

2 urine sample (1 at J0 and 1 at J7)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling

6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)

Intervention Type OTHER

urine sampling

2 urine sample (1 at J0 and 1 at J7)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years old
* Patient with a social security cover.
* Free and informed oral consent given.
* Pneumocystis infection or colonization diagnosed on BAL (Broncho-alveolar liquid) or sputum at Toulouse University hospital Mycology laboratory.
* Adequate Pneumocystis therapy for infected patients (cotrimoxazole).